RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Health resource use and cost analysis of schizophrenia patients participating in a randomized, multicenter, double-blind, relapse prevention study of paliperidone palmitate 3-month formulation
Benson, C., Chirila, C., Graham, J., Radder, C., Zheng, Q., & Woodruff, K. (2015). Health resource use and cost analysis of schizophrenia patients participating in a randomized, multicenter, double-blind, relapse prevention study of paliperidone palmitate 3-month formulation. Value in Health, 18(3), A119. https://doi.org/10.1016/j.jval.2015.03.699
Clinical trial PSY-3012 was a randomized, multicenter, double-blind, parallel-group, relapse-prevention study of paliperidone palmitate 3-month injection (PP3M) versus placebo. Adults with schizophrenia received a once-monthly injection (PP1M) in an open-label (OL) 17-week transition phase, then a single PP3M injection for OL 12-week maintenance. Stabilized subjects were then randomized to PP3M or placebo in the double-blind (DB) phase. Exploratory objectives were to compare health resource utilization (HRU) and costs between PP3M and placebo.